BRIDGEWATER, N.J., March 1, 2018 /PRNewswire/ -- Amneal
Pharmaceuticals has launched oseltamivir phosphate for oral
suspension, the company's AB-rated therapeutic equivalent for
Tamiflu®, in a 6 mg/mL strength. The powder
finished dosage form is made in the U.S.A. and packaged in bottles providing 60 mL
of usable volume after constitution. Amneal's oseltamivir phosphate
for oral suspension joins its oral solid capsule form approved and
launched in July 2017.
"Approval and launch of this liquid form should be of great
assistance to patients and caregivers," states Amneal EVP of
Commercial Operations Andy Boyer.
"With a severe flu season upon us, our product should be able to
help provide relief to thousands of patients. We are pleased
to provide this liquid dosage form to patients, particularly the
elderly and young who are unable to use an oral solid form."
Annual U.S. sales of Tamiflu® and its generic
equivalents were $956 million,
according to December 2017 IQVIA™
market data.
About Amneal
Amneal Pharmaceuticals LLC, a privately-held company
headquartered in Bridgewater, New
Jersey, is one of the largest and the fastest growing
generics pharmaceutical manufacturers in the United States. Founded in 2002, Amneal now
has more than 5,000 employees in North
America, Asia and
Europe, working together to bring
high quality affordable medicines to patients worldwide. Amneal has
significantly expanded its portfolio of generic products to include
complex dosage forms in a broad range of therapeutic areas.
Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. (NASDAQ:
IPXL) announced on October 17, 2017
that they have entered into a definitive business combination
agreement with the resulting combined company expected to create
the 5th largest generics business (by gross revenue) in
the United States. The transaction
is expected to close in the first half of 2018.
For more information, visit amneal.com.
All trademarks listed are property of their respective owners.
Product photo available upon request.
CONTACTS:
Sales
Andy
Boyer
Executive Vice President, Commercial Operations
908.409.6891
andy.boyer@amneal.com
Media
Cheryl Lechok
Media Relations
203.613.1506
mediarelations@amneal.com
Business Development
Apurva
Saraf
Vice President, Global Strategy & Corporate Development
631.742.7674
apurvas@amneal.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/amneal-launches-generic-for-tamiflu-oral-suspension-300606323.html
SOURCE Amneal Pharmaceuticals